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a  b  s  t  r  a  c  t
Surveillance  is fundamental  to  the  management  of head  and  neck  cancer.  The  present  guidelines  of the
French  ENT  society  (SFORL)  were  drawn  up  by  a group  of  experts  in the  ﬁeld,  and are  intended  to  specify
the  modalities  of  management,  based  on a review  of the  literature  and,  where  data  are  lacking,  to provide
expert  opinion.  The  present  paper  deals  with  guidelines  for the  diagnosis  of  local  and regional  recurrence
and  metachronous  head  and  neck  locations.  Locoregional  recurrence  usually  occurs  within  3 years  of
primary  treatment  and  is  mainly  related  to  the  characteristics  of  the  primary  tumor  and  the  treatment
measures  taken.  Laryngeal  location,  safe  primary  resection  margins,  low  level  of lymph  node  invasion,
unimodal  primary  treatment  and  early  diagnosis  of  recurrence  are  factors  of good prognosis.  Systematic
imaging  surveillance  may  be considered  for patients  for  whom  a curative  technique  exists  and  when
surveillance  is  difﬁcult.  The  role  of  PET-scanning  remains  to be determined.  Metachronous  locations  are
frequent,  even  in  the  late  course;  prolonged  surveillance  is  appropriate.  The  best preventive  measure  is
cessation  of alcohol  abuse  and  smoking.  Patient  education  is  primordial.
© 2015  Published  by Elsevier  Masson  SAS.Surveillance is fundamental to the management of head and
eck cancer, and is the responsibility of all practitioners involved
n care.
Ninety-seven percent of patients consider it necessary [1] (level
f evidence 4).
The present guidelines were drawn up by a multidisciplinary
roup of experts in the ﬁeld: ENT specialists, and also radiothera-
ists and oncologists. They are intended to specify the modalities of
anagement, based on a study of the literature and, where data are
acking, on expert opinion. Nasopharynx, facial sinus, and salivary
nd thyroid gland cancer were excluded.
The present paper deals with guidelines for the diagnosis of
ocal and regional recurrence and metachronous head and neck
ocations.
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Diagnosis is essential, especially in high-risk patients and those
for whom curative measures are available.
Diagnosis of locoregional recurrence begins 6 months after the
end of primary treatment and is intended to determine curative
treatment [2] (level of evidence 2).
Local recurrence induces lymph node recurrence, which in turn
induces metastasis [3,4] (level of evidence 4).
Early diagnosis enables treatment with curative intent and
improves survival [3,5] (level of evidence 4), [6] (level of evidence
2).
1.1. Time to onset of local recurrenceLocoregional recurrence, estimated at 15–35%, is usually local.
Onset in 90% of cases is within 3 years of primary treatment [2]
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vidence 4). De Raucourt et al. estimated recurrence rates at 21%
y 2 years and 25% by 3 years [9] (level of evidence 4).
Guideline
• Locoregional recurrence should be screened for during the
ﬁrst 3 years (expert opinion).
.2. Risk factors for locoregional recurrence
Risk factors are mainly related to primary tumor characteristics
nd treatment modalities.
Recurrence rates are higher in pharyngeal than laryngeal tumor.
ccording to Boysen et al. [2] (level of evidence 2) and Haas et al.
3] (level of evidence 4), recurrence rates are independent of tumor
ocation and are lower only for T1 tumor. N0 tumor shows less
ymph node recurrence, which is very high in N3 tumor [3] (level
f evidence 4).
Abstention from lymph node surgery incurs a high-risk of lymph
ode recurrence, especially in oral cavity cancer [10] (level of evi-
ence 2).
Histologically, well-differentiated squamous cell carcinoma
hows the lowest rate of local recurrence [1] (level of evidence 2).
Positive margins [11] (level of evidence 4) and perineural inva-
ion [12] (level of evidence 4) increase the risk of local recurrence.
HPV+ tumor shows less local recurrence [13] (level of evidence
). In oropharyngeal HPV+ tumor, smoking is the main risk factor
or local recurrence [14] (level of evidence 2).
.3. Patients in whom early diagnosis of recurrence may
nﬂuence survival
Survival rate for patients with recurrence or in whom a second
ocation is discovered is very low: 16% at 5 years according to Haas
t al. [3] (level of evidence 4).
In advanced recurrence, treatment is curative in only 5% of cases
15] (level of evidence 4).
Time to onset of recurrence does not correlate with survival
16] (level of evidence 2). Laryngeal primary tumor is associated
ith optimum survival in case of second location, probably due
o primary tumor stage, which is usually T1 or T2N0, managed
y exclusive surgery allowing salvage surgery and radiation ther-
py [3] (level of evidence 4). The success rate for treatment of
ecurrence of laryngeal tumor is nearly 85%, versus 35% for other
ocations [16] (level of evidence 2).
Early diagnosis of recurrence inﬂuences survival, which is fur-
her correlated with the TNr stage rather than with primary stage,
r stage being more inﬂuential than Tr stage [17] (level of evidence
).
Success of tumor salvage treatment is high only with uni-
odal primary treatment; authors therefore recommend intensive
urveillance following unimodal treatment, as treatment will be
ith curative intent in case of recurrence [2] (level of evidence 2),
3] (level of evidence 4).
.4. Contribution of systematic examination in screening for
ecurrence
Treatment with curative intent is usually feasible in asymp-
omatic patients [1] (level of evidence 2), arguing strongly for
ystematic consultation, preferably by a head and neck specialist.
oysen et al. reported a higher rate of tumor detection in case of
ymptomatic lesion [2] (level of evidence 2), without signiﬁcantgy, Head and Neck diseases 132 (2015) 287–290
impact on survival. The literature ﬁndings are sometimes con-
tradictory; some authors report higher detection rates in control
consultations without functional complaint [3] (level of evidence
4), while others, such as Flynn et al. [12] (level of evidence 4),
reported much higher recurrence discovery rates in consultations
for functional complaints.
Surveillance should certainly be systematic, while informing
patients for the possible need of extra consultations in case of onset
of symptoms suggestive of recurrence.
1.5. Contribution of endoscopy in recurrence screening
There have been no studies of the contribution of panendoscopy
to surveillance. The consensus is that it should be scheduled accord-
ing to symptoms or examination ﬁndings, preferably after imaging,
to guide biopsy [18,19] (expert opinion).
1.6. Contribution of biological examination
There are no speciﬁc biological markers for the diagnosis and
follow-up of head and neck cancer, other than in the nasopharynx.
1.7. Contribution of imaging
1.7.1. Contribution of CT in screening for local and lymph node
recurrence
In an organ-sparing protocol, Hermans reported earlier recur-
rence detection on CT than on clinical or ﬁberoptic examination,
probably due to the submucosal primary location [20] (level of
evidence 4). Progression assessment therefore requires baseline
imaging as part of the posttreatment check-up.
Jung et al. [8] (level of evidence 4), in a retrospective study of 520
patients, reported that 53% of recurrences were diagnosed by the
specialist, 25% by the patient and 22% on systematic imaging follow-
ing multimodal treatment of advanced tumor; patients receiving
surgery showed less local recurrence, and local recurrence was
more often detected by specialists whereas regional recurrence and
metastasis were more often detected on complementary examina-
tion.
Systematic imaging surveillance may  be considered for patients
for whom a curative treatment is available or in whom clinical and
endoscopic surveillance is problematic (e.g., following radiation
therapy).
1.7.2. Contribution of PET-CT in screening for local and regional
recurrence
Studies using systematic PET-CT in follow-up reported a 30%
rate of tumoral events at 1 year’s surveillance [21] (level of evi-
dence 4), [22,23] (level of evidence 2). Beswick et al. reported that
95% of recurrences occurred within 24 months, and that there is
no interest in continuing PET-CT systematically after that time [21]
(level of evidence 4).
In a meta-analysis of 55 studies with more than 2355 patients,
Gupta et al. reported insufﬁcient positive predictive value (58%)
with PET-CT; the very good negative predictive value (95%), how-
ever, helps avoid unnecessary invasive examination [24] (level of
evidence 1).
PET-CT is currently recommended in difﬁcult cases with sus-
pected tumor but negative biopsy or when assessment fails to
account for symptoms, especially when CT and MTI  prove non-
contributive. It should be performed late after biopsy, to avoid false
positives.
A prospective study of survival and medico-economic aspects
could determine the surveillance role of PET-CT and patient selec-
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. Metachronous locations at the level the upper
erodigestive tract (UADT)
Populations at risk of second location: all patients with an initial
ocation at the UADT are at signiﬁcant risk of second location, esti-
ated at 2–4% per year for 10 years or more [25] (level of evidence
). In the ﬁrst 3 years, the main risk is of locoregional recurrence.
urveillance should thereafter focus on secondary locations [9]
level of evidence 4).
Patients with an initial location at the UADT show a cumula-
ive rate of metachronous second head and neck location of 56% by
5 years, on a linear curve not diminishing over time [9] (level of
vidence 4).
Prolonged surveillance is therefore mandatory.
Some patients are at higher risk of developing a metachronous
econd location.
.1. Risk related to social history for tobacco and alcohol
Smoking and alcohol abuse are risk factors for secondary cancer
26] (level of evidence 2).
Cessation of smoking reduces risk [27] (level of evidence 2) and,
ccording to Murakami et al., withdrawal from smoking and alcohol
s the best preventive measure [28] (level of evidence 4).
.2. Risk related to tumor location
The oropharynx and oral cavity are the sites where second loca-
ions are the most frequent [25] (level of evidence 4). Haughey
t al., in a meta-analysis including 3706 patients, reported 67%,
3%, 43% and 30% rates of second location for primary cancers of
he oropharynx, oral cavity, hypopharynx and larynx, respectively;
hese rates were inversed for pulmonary secondary locations [29]
level of evidence 2).
.3. Risk related to tumor characteristics
Tumor stage, histologic type and lymph node status do not seem
o affect secondary onset.
Resection margins, likewise, do not affect secondary locations,
lthough they are an essential factor in local recurrence.
Two retrospective studies showed that HPV+ oropharyngeal
umor shows signiﬁcantly less risk of second location occurrence
30,31] (level of evidence 4).
.4. Risk related to treatment
Several prospective studies reported similar secondary location
ates with radiation therapy and concomitant radio-chemotherapy
ollowing surgery [15,32,33] (level of evidence 1).
. Patient selection for early diagnosis of secondary head
nd neck location
Second head and neck location is the most frequent and easiest
o diagnose, being accessible to clinical examination, and shows the
est prognosis: 20% survival, versus 3% for the esophagus and 2%
or the lung, according to Schwartz et al. [26] (level of evidence 2).
atients who have never smoked or shown alcohol abuse can be
xcluded from such surveillance [26,34] (level of evidence 2).
The interest of systematic surveillance is controversial. Boysen
t al. insisted on patient education, encouraging consultation for
ny abnormal sign [2] (level of evidence 2).
de Visscher and Manni, in contrast, in a 1994 study of 428
atients, found better survival after early event screening than after
eturn to consultation for symptoms [1] (level of evidence 4), andgy, Head and Neck diseases 132 (2015) 287–290 289
therefore considered surveillance, like psychological follow-up, to
be indispensable.
Finally, although survival beneﬁt remains unproven, screening
for metachronous cancer appears justiﬁed in patients at high-risk
according to the above-mentioned criteria. This is especially true
for secondary head and neck locations, which are most accessible
to treatment with curative intent.
3.1. Contribution of systematic clinical examination in screening
for secondary head and neck locations
3.1.1. Surveillance consultation
The size of asymptomatic tumors discovered on scheduled con-
sultation is not signiﬁcantly smaller than that of symptomatic
tumors, and survival is identical [9] (level of evidence 2).
Some authors therefore question the usefulness of systematic
consultation, highlighting rather the importance of patient educa-
tion [2] (level of evidence 2).
3.1.2. Contribution of endoscopy in screening for second locations
at the level of the UADT
Panendoscopy is not systematic; it should be performed only in
the case of a doubtful diagnosis, a particular symptom or to enable
biopsy (expert opinion).
Only two reports recommended systematic panendoscopy, but
without demonstrating efﬁcacy and beneﬁt: once yearly for Di Mar-
tino et al. [25] (level of evidence 4), and twice yearly for Narayana
et al. [35] (level of evidence 2).
3.2. Biological examination
Serum tumor markers show poor sensitivity for the diagnosis
and follow-up of head and neck cancer.
3.3. Imaging
Imaging should be guided by clinical examination.
Purely mucosal locations are poorly visualized on CT and MRI.
PET-CT is mainly useful in screening for recurrence and is not
very cost-effective for second cancer: events are infrequent (5% at
6 months and 4% at 1 year) and sensitivity is 29% at 3–6 months and
80% at 1 year. The study by Kim et al. was alone in reporting sec-
ond (metachronous) cancer, but most cases were not necessarily
related to smoking (nasopharynx, thyroid, prostate, stomach) and
were therefore sometimes discovered serendipitously; with annual
secondary incidence at 4%, the cost of such “screening” becomes
problematic [22] (level of evidence 2).
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